Clinical trials
Neuromyelitis Optica clinical trials
Below are recruiting neuromyelitis optica clinical trials, each written for real people, not researchers. We’re tracking 39 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07738952RecruitingPhase 1/Phase 2
Sivelestat for neuromyelitis optica spectrum disorder relapses
This study tests a drug called sivelestat for people with neuromyelitis optica spectrum disorder (NMOSD) who are having a relapse. The drug may help reduce damage during the relapse and improve recovery.
FukuokaAges 18 years+ - NCT07420296RecruitingPhase 3
Modified zipper therapy for AQP4-positive neuromyelitis optica
This trial tests a new treatment called modified zipper therapy for people with neuromyelitis optica spectrum disorder (NMOSD) who have a specific antibody (AQP4-IgG) in their blood. It aims to stop a recent attack and improve recovery.
TianjinAges 18–80 - NCT06763848Recruiting
Blood filtering for NMOSD attacks
This trial tests a blood filtering procedure called Protein A immunoadsorption for people having an acute episode of neuromyelitis optica spectrum disorder (NMOSD). It may help remove harmful antibodies from your blood and reduce symptoms.
Guangzhou, GuangdongAges 18–65 - NCT06620809RecruitingPhase 1
New treatment for neuromyelitis optica flare-ups
This trial tests a new medicine (NouvSoma001) for people with neuromyelitis optica (NMOSD) who are having a flare-up. The goal is to see if the treatment is safe and if it helps reduce symptoms like pain and trouble moving.
Wuhan, HubeiAges 18–65 - NCT06398158Recruiting
Ravulizumab and its impact on neuromyelitis optica
This study looks at how well ravulizumab (Ultomiris) works for people with neuromyelitis optica spectrum disorder (NMOSD) by tracking symptoms and MRI scans over time. It aims to see if the drug helps control the disease in real-world use.
Dallas, TexasAges 18 years+ - NCT06374264Enrolling by invitation
Music-based walking therapy for NMOSD
This trial tests a music-based walking therapy (called MR-C-014) to see if it is safe and well-tolerated for people with NMOSD who have trouble walking. It may help improve your walking pattern and strength.
Atlanta, GeorgiaAges 18–70 - NCT05549258RecruitingPhase 2
Inebilizumab for children with NMOSD who had recent relapses
This trial studies whether inebilizumab can reduce illness activity in children with neuromyelitis optica spectrum disorder (NMOSD), a condition that can cause attacks affecting the eyes and spinal cord. It focuses on kids who have had recent relapses, meaning symptoms came back or worsened.
La Jolla, CaliforniaAges 2–17 - NCT06413654RecruitingPhase 2/Phase 3
B001 for NMOSD: reducing relapses
This trial tests an investigational drug called B001 for people with NMOSD who have had recent relapses. The goal is to see if it can reduce future flare-ups.
BeijingAges 18 years+ - NCT05199688RecruitingPhase 3
Satralizumab for children with AQP4-positive NMOSD attacks
This trial studies satralizumab in children ages 2 to 11 with a specific type of NMOSD caused by AQP4 antibodies. It aims to see how well the medicine prevents attacks and is safe over time.
Denver, ColoradoAges 2–11 - NCT04886492Enrolling by invitation
NMOSD patient registry to help study future treatments
This is a registry that collects health information from adults with neuromyelitis optica spectrum disorder (NMOSD). It aims to better understand NMOSD and support future research, including studies of emerging therapies.
Waltham, MassachusettsAges 18 years+ - NCT07557420RecruitingPhase 3
Ravulizumab for Neuromyelitis Optica Spectrum Disorder in Chinese Adults
This study tests a new medicine called ravulizumab (an infusion) to reduce relapses in people with neuromyelitis optica spectrum disorder (NMOSD), a rare condition affecting the optic nerve and spinal cord. The trial is specifically enrolling adults in China who have had recent disease activity.
BeijingAges 18–130 - NCT05909761Recruiting
Pregnancy Uplizna safety study in women with NMOSD
This is an observational study that looks at the safety of Uplizna (satralizumab) during pregnancy for women who have neuromyelitis optica spectrum disorder (NMOSD). You may be asked to share information because your exposure to Uplizna happened during pregnancy or just before conception.
Aurora, ColoradoAges 15 years+ - NCT06865274Recruiting
A look at gene changes in MS, NMOSD, and MOGAD
This study looks at a specific gene change in people with MS, NMOSD, or MOGAD to see how common it is. By joining, you help researchers learn more about these conditions and possible future treatments.
Roma, RomaAges 18 years+ - NCT06697535RecruitingPhase 2
Study of JYP0061 for acute NMOSD attacks
This trial tests a new medication called JYP0061 for people with NMOSD who are currently experiencing a sudden worsening of symptoms (acute attack). It aims to see if the drug can help control the attack and improve outcomes.
Changsha, HunanAges 18–65 - NCT05204459Recruiting
MRI and eye-scan study for MS and related conditions
This trial uses brain MRI and eye imaging tests to study research markers in people with multiple sclerosis (MS) and related neurologic conditions. It may help researchers better understand these diseases and how they change over time.
Los Angeles, CaliforniaAges 18 years+ - NCT06541626Recruiting
Study of CNS inflammatory demyelinating diseases
This study follows people with certain inflammatory conditions of the brain and spinal cord (like MS, NMOSD, or MOGAD) to learn more about their disease. If you join, you will help researchers understand these conditions better.
Guangzhou, GuangdongAges 18–65 - NCT07762872Recruiting
Satralizumab during early NMOSD attacks
This study looks at how well the medication satralizumab works when started early during an NMOSD attack, along with standard treatments. The aim is to see if adding this drug can help reduce the impact of the attack and improve outcomes.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06474520Recruiting
Bovine gallstone extract for inflammatory brain disease
This trial tests a natural substance called Calculus Bovis Sativus (CBS) to see if it helps people with certain inflammatory brain conditions like multiple sclerosis, neuromyelitis optica, MOGAD, or ADEM. The goal is to find out if it is safe and effective.
Wuhan, HubeiAges 18 years+ - NCT04561557RecruitingEarly Phase 1
Cell therapy for relapsing nervous system autoimmune diseases
This early-phase trial tests CT103A “CAR-T” cell therapy to treat certain relapsing or treatment-resistant autoimmune diseases that affect the nervous system. It aims to see whether the cells are safe and may help reduce disease activity when standard treatments haven’t controlled symptoms.
Wuhan, HubeiAges 18–75 - NCT07653984Recruiting
Study on immune diseases in women of childbearing age
This study follows women with certain immune disorders affecting the nervous system (like multiple sclerosis or myasthenia gravis) to understand how these conditions affect reproduction. Healthy women planning pregnancy are also included for comparison.
Guangzhou, GuangdongAges 20–55 - NCT07636876Enrolling by invitation
Italian MS and Related Disorders Patient Registry
This is a registry study that collects health information from people with multiple sclerosis and related conditions. By joining, you help researchers better understand these diseases and improve future treatments.
Genova, GenovaAges Any age - NCT05017142Recruiting
Pediatric brain inflammation registry for Swiss patients
This study is a registry that collects health information from children and teens in Switzerland diagnosed with certain inflammatory brain and spinal cord conditions. It helps researchers understand these illnesses better over time and may guide future treatments.
Aarau, Canton of AargauAges Up to 36 years - NCT07526493RecruitingPhase 1
QH103 Cell Therapy for Resistant Autoimmune Nerve and Brain Diseases
This Phase 1 trial tests whether QH103 cell injections can help patients with serious autoimmune diseases affecting nerves and the brain (like MS, NMOSD, myasthenia gravis, and others) that haven't responded well to standard treatments. The goal is to evaluate safety and whether the treatment helps reduce symptoms.
Wuhan, HubeiAges 18–75 - NCT07410039RecruitingPhase 4
Acute treatment for neuromyelitis optica in real-world setting
This study looks at treatments for people with neuromyelitis optica spectrum disorder (NMOSD) who are having a sudden attack affecting their vision or spinal cord. It aims to find out which treatments work best in everyday practice.
BeijingAges 18–65
Hear when a new Neuromyelitis Optica trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for neuromyelitis optica?
- Yes. Clin2 currently lists 39 recruiting neuromyelitis optica studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a neuromyelitis optica trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a neuromyelitis optica trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.